Active, not recruitingNCT05064553
ALTUS: Performance of a Multi- Target Hepatocellular Carcinoma (HCC) Test in Subjects With Increased Risk
Studying Carcinoma of liver and intrahepatic biliary tract
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Exact Sciences Corporation
- Principal Investigator
- Binu JohnMiami VA Healthcare System
- Intervention
- Study CT/MRI Imaging(device)
- Enrollment
- 2990 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2021 – 2026
Study locations (30)
- Arizona Health Research, Chandler, Arizona, United States
- Arizona Digestive Health - Sun City, Sun City, Arizona, United States
- Franco Felizarta, MD, Bakersfield, California, United States
- Gastroenterology & Liver Institute, Escondido, California, United States
- Cedars Sinai Medical Center, Los Angeles, California, United States
- Providence Facey Medical Foundation, Mission Hills, California, United States
- United Medical Doctors, Murrieta, California, United States
- VA Palo Alto Healthcare System, Palo Alto, California, United States
- Stanford University Medical Center, Palo Alto, California, United States
- California Liver Research Institute, Pasadena, California, United States
- Cadena Care Institute, Poway, California, United States
- Inland Empire Clinical Trials, Rialto, California, United States
- Research & Education, Inc, San Diego, California, United States
- San Jose Gastroenterology, San Jose, California, United States
- Rocky Mountain Gastroenterology, Littleton, Colorado, United States
- +15 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT05064553 on ClinicalTrials.govOther trials for Carcinoma of liver and intrahepatic biliary tract
Additional recruiting or active studies for the same condition.
- ACTIVE NOT RECRUITINGNCT07437859Exploring the Application of 3D Bioprinting for Personalized Treatment in Primary Liver Cancer With Tumor MicroenvironmentPeking Union Medical College Hospital
- RECRUITINGPHASE1NCT07106827A Study of GV20-0251 in Advanced or Refractory Solid TumorsWest China Hospital
- RECRUITINGNCT07466602cfDNA Methylation for Liver Cancer Recurrence DetectionWuhan Ammunition Life-tech Co., Ltd
- RECRUITINGPHASE2NCT07105748HAIC Combined With Camrelizumab Plus Rivoceranib for Advanced Mixed Hepatocellular-cholangiocarcinoma (HCC-CCA)Fudan University
- RECRUITINGPHASE2NCT06766643Stereotactic Radiosurgery Versus Radiofrequency Ablation for Primary Liver CancerTianjin Medical University Cancer Institute and Hospital
- RECRUITINGNCT06849180Novel Subtypes and Treatment Strategies of Patients with Unresectable Combined Hepatocellular Cholangiocarcinoma Based on Multimodal DataZhongda Hospital
- RECRUITINGNANCT06905015Stroke Volume Variation Versus Central Venous Pressure Guidance for Reducing Perioperative Blood Loss During Open Liver ResectionWarangkana Lapisatepun
- RECRUITINGNCT06486454Real-world Evaluation of the HistoSonics Edison System for Treatment of Liver Tumors Across Multidisciplinary Users (BOOMBOX: Master Study)HistoSonics, Inc.
See all trials for Carcinoma of liver and intrahepatic biliary tract →